Australia's most trusted source of pharma news
Saturday, 28 May 2016
Lost Your Access?
Former Sigma CEO, CFO sentenced
The former managing director and CEO of Sigma Elmo De Alwis and CFO Mark Smith have been sentenced and fined after pleading guilty to falsifying the company's records in 2009 and 2010.
Gilead leads PBS on HCV surge
PBS spending as measured by date of processing figures spiked in April on the back of a massive surge in spending on new HCV drugs, driving Gilead to the top of the origintor pile on a monthly basis.
Greens will bypass PBS for PrEP
The Greens are promising $34.4 million to fund Gilead's
as pre-exposure prophylaxis if the drug does not win PBAC recommendation for PBS listing.
Pharma marketing needs to move on
Starting with customers and content generation are the way to go, says Novartis executive.
NOACs safe, effects similar to warfarin
A new Australian post-market study has not identified an increased risk of bleeding associated with the use of the NOACs and found efficacy similar to warfarin.
GSK promotes new COPD data
GSK is spruiking new data showing the efficacy of its new COPD hope
to further cement its position in a crowded market.
CSL hails more US success
CSL is on a roll in the US, revealing its novel long-lasting recombinant factor VIII single-chain therapy for haemophilia A,
, has won FDA approval.
Cancer register decision under fire
The award of a $220 million government tender for the National Cancer Screening Register to Telstra Health has come under strong fire.
GPs name their top info sources
GPs still regard conversations with specialists as their number one source of credible information but reliance on online clinical journals is growing and reps have a particular place.
PBS hardball frustrates diabetes expert
New diabetes medicines, and probably other innovative medicines too, are not being brought to Australia because of the government's hardball negotiation on pricing, says a diabetes specialist.
PBS swallowed Medicare cash: Turnbull
Prime Minister Malcolm Turnbull has defended his government's indefinite freeze on Medicare rebates by saying the savings were spent on new PBS drugs.
Risk-sharing may go wider: PBAC chair
PBAC chair Professor Andrew Wilson has said the earlier medicines come to the committee the more pressure is created for a wider view of risk-sharing with sponsors.
Companies spending more on HCOs
Some companies have chosen to publish their 2015 HCO funding reports ahead of MA's official schedule, revealing considerably larger spends than in 2014.
Sanofi and Health at impasse over Toujeo
Despite a year of negotiations with the Department of Health Sanofi says next generation insulin glargine
is unlikely to be PBS listed in the forseeable future.
Infliximab biosim data confirms efficacy
Biosimilar infliximab has been shown to be efficacious over the long-term and is not associated with any detrimental effects on efficacy, immunogenicity or safety in patients who switch to it, a new study reports.
Lilly: 20 new products in a decade
Eli Lilly has claimed it can launch 20 new products over 10 years concentrating on five therapeutic areas: diabetes, oncology, immunology, neurodegeneration and pain.
Aust study questions back pain drug use
Using opioids for chronic low back pain is no better than treating it with NSAIDs says new Australian research.
AFT rides new product wave
The NZ-based maker of
reports a boost in income after new product launches but still expects a loss in 2017.
PRIME expands beyond awards
The 2016 PRIME Awards are open for entries now and the brand is expanding into previously unexplored territory.
Time to fully embrace multichannel marketing
Starting with the customer and increasing your content is the way to create engaging marketing campaigns, says a Novartis executive.
Biosim threat stalks Mabthera
The EMA has accepted for review Sandoz's biosim of Roche's
has won a EC approval for myeloma.
GSK's volunteer program is changing lives
Australian GSK staff who participate in the company's international volunteer programs say it changes not only the lives of those they help but also their own.
New anti-lipid market warms up
The registration of Sanofi's PCSK9 inhibitor Praluent (alirocumab) marks the arrival in Australia of the second among the new class of lipid-lowering drugs.
What chances drug patent regime will change this time?
The latest set of recommendations for reform of the pharma IP system are only the latest in a long and unsuccessful history of attempts to change the status quo. Will their fate be similar?
Events & Conferences
© 2003 - 2016 Lush Media
Pharma in Focus
Jolly Good Design